About Superluminal Medicines
Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform quickly creates candidate-ready compounds using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. They leverage cutting-edge computational and machine-learning techniques to accelerate identifying and optimizing novel drug candidates. Their approach combines high-throughput experimental data with advanced algorithms to uncover therapeutic compounds faster and more efficiently than traditional methods.
Open positions (4)
Company details
Funding
Total raised
$158M
Last stage
Series A
Investors
Founders
Cony D'Cruz
Co-founder and CEO of Superluminal Medicines. Previously a Schrödinger alum. Led the company from its origins as a stealth project at RA Capital Management.
Ajay Yekkirala
PhD; former postdoc at Harvard Medical School and Boston Children's Hospital; previously VP, Head of Biology at RA Capital Management; co-founder of Blue Therapeutics.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.